Tucidinostat - HUYA Bioscience International
Alternative Names: Chidamide; CS-055; Epidaza; HBI-8000; HiyastaLatest Information Update: 06 Mar 2024
At a glance
- Originator Chipscreen Biosciences
- Developer Bristol-Myers Squibb; Chipscreen Biosciences; GNT Biotech and Medicals Corporation; Guangxi Center for Disease Control and Prevention; HUYA Bioscience International; Meiji Seika Pharma; Zhejiang University
- Class Acrylamides; Aminopyridines; Antineoplastics; Antivirals; Benzamides; Fluorinated hydrocarbons; Small molecules
- Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; HDAC1 protein inhibitors; HDAC10 protein inhibitors; HDAC2 protein inhibitors; HDAC3 protein inhibitors; Mitogen-activated protein kinase inhibitors; Proto oncogene protein c-akt inhibitors; Ras protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Adult T-cell leukaemia-lymphoma; Breast cancer; Peripheral T-cell lymphoma
- Preregistration Diffuse large B cell lymphoma
- Phase III Brain metastases; Malignant melanoma
- Phase II/III Cutaneous T-cell lymphoma; HIV infections
- Phase II Non-small cell lung cancer
- Phase I/II Liver cancer; Non-Hodgkin's lymphoma; Solid tumours
Most Recent Events
- 22 Feb 2024 Phase-II clinical trials in Peripheral T-cell lymphoma (Second-line therapy or greater) in Taiwan (PO) (NCT05833724)
- 01 Feb 2024 Phase-III clinical trials in Peripheral T-cell lymphoma (Second-line therapy or greater, Combination therapy) in Japan (PO) (NCT06122389)
- 30 Sep 2023 HUYA Bioscience International completes a phase I/II trial for Solid tumours (Combination therapy, Late-stage disease) in USA (PO,Tablet) (NCT02718066)